Overview

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Patients with advanced or recurrent adenocarcinoma or adenosquamous cell carcinoma of the cervix will receive Pemetrexed.
Phase:
Phase 2
Details
Lead Sponsor:
Western Regional Medical Center
Treatments:
Pemetrexed